Just caught something interesting brewing in the uranium space. India's nuclear program is accelerating fast, and Cameco just locked in a massive 9-year supply deal worth around $1.9 billion. We're talking nearly 22 million pounds of uranium concentrate starting in 2027.



What's really driving this is India's energy ambitions. They've got 24 reactors running now with 7,000+ MW capacity, six more under construction adding another 4,700 MW, and they're targeting 100 GW by 2047. That's serious scaling for a country with 1.4 billion people and energy demand growing faster than anywhere else. Plus, India just opened their nuclear sector to private investment last December and eased liability rules that were holding back expansion.

Cameco's sitting pretty for this. They own massive chunks of the world's best uranium assets - 69% of McArthur River (the world's largest high-grade uranium mine), 83% of Key Lake (world's largest uranium mill), and 54% of Cigar Lake (highest-grade uranium mine). Their cost structure is built into the lower quartile formula that makes them competitive even when prices fluctuate. They've already got 230 million pounds sold to 39 customers globally, so this India deal just adds to their locked-in revenue stream.

But Cameco's not the only one eyeing this opportunity. NexGen Energy's Rook I Project in Saskatchewan is being positioned as the world's biggest low-cost uranium source, potentially hitting 30 million pounds annually at lower quartile costs around C$13.86. That could triple Canada's uranium output. Energy Fuels is ramping up U.S. production and just expanded into rare earths and medical isotopes. Uranium Energy's pushing their in-situ recovery tech across multiple hubs.

The structural demand is real - global decarbonization, energy security concerns, and governments locking in fuel supplies from multiple sources. India's nuclear push is just one piece of it, but it's a significant one. The uranium sector's definitely worth watching right now.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin